Õ¹¿ª

ҽѧУÑé·¶ÎÄÏËάµ°°×Ô­²â¶¨ÔÚÁÙ´²ÉϵÄÓ¦ÓüÛÖµ(2)

·¢²¼Ê±¼ä£º2014-10-10   |  ËùÊô·ÖÀࣺҽѧУÑ飺ÂÛÎÄ·¢±í  |  ä¯ÀÀ£º  |  ¼ÓÈëÊÕ²Ø

¡¡¡¡5ÏËάµ°°×Ô­ÓëÁÙ²ú¸¾Å®

¡¡¡¡ÏÖ´úΧÉúҽѧ±¨µÀ£¬Ëæ×ÅҽѧµÄ·¢Õ¹£¬²ú¿ÆËÀÍöÂʸߵÄËÄ´ó¼²²¡£¬°üÀ¨ÈÑÉïºÏ²¢ÐÄÔಡ¡¢ÑÏÖØÈѸßÕ÷¡¢²úºó³öѪÒÔ¼°²úÈì¸ÐȾµÄÖÎÁÆÐ§¹ûÓÐÃ÷ÏÔÌá¸ß£¬ËÀÍöÂÊϽµ¡£È»¶ø£¬ÓÉÓÚÈÑÉïÄ©ÆÚÏËάµ°°×Ô­´ó·ù¶ÈÉý¸ßËùÐγɵÄÉúÀíÐÔ¸ßÄý¡¢¸ßÕ³¶È״̬£¬ÔÚ¼ÓÉϵ¨¹Ì´¼¼°Ö¬´úлÒì³££¬µ¼ÖÂÌ¥ÅÌѪ¹ÜÖàÑùÓ²»¯£¬Ó°ÏìѪÁ÷Á¿£¬ËðÉËѪ¹ÜÄÚÆ¤£¬´Ùʹ΢Ѫ˨ÐγÉ[12]¡£ÄýѪÓ뿹ÄýϵͳµÄʧºâ£¬ÐγɵÄÉ¾²ÂöѪ˨ÍÑÂ䣬Ôì³É·Î˨Èû£¬³£³£´ëÊÖ²»¼°£¬Ôì³ÉÑÏÖØµÄºó¹û¡£½üÄêÀ´µÄÑо¿·¢ÏÖ£¬Ñª½¬ÏËάµ°°×ԭˮƽÔö¸ß±íÏÖLDLºÍTGˮƽÔö¸ß¡£ÌرðÊǸßTGѪ֢ʱ£¬¸ÎÔàºÏ³É¼«µÍÃܶÈÖ¬µ°°×Ôö¼Óʱ£¬Òà°éÓÐÄýѪÒò×ӺϳÉÔö¼Ó£¬¸»º¬TGµÄÖ¬µ°°×µÄÄýѪÒò×Ó½Ó´¥ºó£¬¿ÉʹÄýѪÒò×Ӻϳɴ¦ÓÚ¼¤»î״̬£¬ÑªÒºÔò´¦ÓÚ¸ßÄý״̬[13]¡£Òò´Ë£¬Á˽âÔвú¸¾²úǰ¡¢²úºóµÄѪ½¬ÏËάµ°°×ԭˮƽ£¬¼°Ôç²ÉÈ¡Êʵ±µÄÖÎÁÆ´ëÊ©£¬½µµÍºÍ¸ÉÔ¤Ôвú¸¾µÄÏËάµ°°×ԭˮƽ£¬¶ÔÓÚÔ¤·ÀºÍ±ÜÃâ·¢ÉúѪ˨ÐÔ¼²²¡ÒÔ¼°ÆäËüµÄÑÏÖØ²¢·¢Ö¢£¬Ìá¸ßÔвú¸¾µÄÉú´æÖÊÁ¿½«ÓнÏʵÓõÄÁÙ´²¼ÛÖµ¡£×ÜÖ®£¬Ñª½¬ÏËάµ°°×Ô­º¬Á¿µÄ¸Ä±ä£¬ÊÇ»úÌåµÄÒ»ÖÖ·ÇÌØÒìÐÔ·´Ó¦£¬ÔÚÐÄѪ¹Ü¼²²¡¡¢¼±ÐÔÑ×Ö¢¡¢ÌÇÄò²¡¡¢¶ñÐÔÖ×Áö¾ù·¢Éú²»Í¬³Ì¶ÈµÄÔö¸ß¡£ÓÖÓÉÓÚËü²úÉúÓÚ¸ÎÔ࣬¹Ê¸ÎÔàÑÏÖØ²¡±ä£¬Èç¸ÎÓ²»¯¡¢Öж¾ÐÔ¸ÎÑ׵ȿɳöÏÖ¼õµÍ¡£Òò´Ë£¬Ñª½¬ÏËάµ°°×º¬Á¿µÄ²â¶¨£¬ÔÚÁÙ´²ÖоßÓÐÖØÒªÒâÒå¡£

¡¡¡¡½áÊøÓï

¡¡¡¡Ö°³ÆÂÛÎÄ·¶ÎÄÊÇÒ»¼ÒȨÍþµÄ´óÐͳÏÐźËÐÄÆÚ¿¯ÂÛÎÄ·¢±í¡¢Ö°³ÆÂÛÎÄ·¶ÎÄ·¢±íÍø¡£ÍøÕ¾¸²¸Ç½ÌÓýÆÚ¿¯ÂÛÎÄ·¢±í¡¢Ò½Ñ§ÆÚ¿¯ÔÓ־Ͷ¸åµÈÈÈÃÅÐÐÒµ£¬ÊÇÒ»¸öרҵ´ÓÊÂÆÀÖ°ÂÛÎÄ·¢±í,ºËÐÄÆÚ¿¯Õ÷¸å,ºËÐÄÆÚ¿¯·¢±í,ѧÊõÂÛÎÄ·¢±íµÈ·þÎñµÄÂÛÎÄ·¢±íÆÚ¿¯Íø,ÊÇÄúÆÀÖ°³Æ¡¢·¢ÂÛÎÄ×îȨÍþµÄÆÚ¿¯Í¶¸åƽ̨¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡1.Yarnell JWG,Baker IA,Sweetnam PM,et al.Fibrinogen,viscosity,and white blood cell count are major risk factors for ischemic heart disease,Tcaerphilly and speed well collaborative heart daiseases studies[J].Circulation,1991:83:836

¡¡¡¡2.Koh KK,Horne 111 MK,Cannon 111 RO.Effects of hormone replace ment therapy on coagulation,fibrinolysis,and thrombosis risk in post menopausal women[J].Thrombosis and Haemostasis,1999,82:626

¡¡¡¡3.¡¡Àî¼ÒÔö£¬ºØÊ¯ÁÖ£¬ÍõºèÀû.Ѫ˨¼²²¡Ñ§[M].ÉϺ££ºÉϺ£¿Æ¼¼³ö°æÉ磬1998.243

¡¡¡¡4.¡¡ÑîÀò.ÏËάµ°°×Ô­ÓëѪ˨ÐÔ¼²²¡[J].ÖлªÑªÒºÑ§ÔÓÖ¾£¬1999£¬20£º163

¡¡¡¡5.¡¡Stolpe A,Jacobs N,Haje WJ,et al.Fibrnogen binding to ICAM- 1 to EA.hy 926 endthelial cell is dependent on an in tact cytoske leton,Thromb [J].Thromb Hacmost,1996,75:182

¡¡¡¡6.¡¡ÖܵÀÒø£¬Ò×±õ£¬Ê¯ÀÚ£¬µÈ.ÏËά½áºÏµ°°×¡¢ÏËάµ°°×Ô­¼°ÄýѪøԭʱ¼äÔÚ¸ÎÓ²»¯¡¢¸Î°©ÖеÄÒâÒå[J].ÁÙ´²¸Îµ¨²¡ÔÓÖ¾£¬1998£¬14(4)£º224

¡¡¡¡7.¡¡Kannel WB£¬Agostino RB,Wilson PWF,et al.Diabetes,fibriongen and risk of cardiovascular disease:the Framingham experrence[J].Am Heart J,1990,120(3):672

¡¡¡¡8.¡¡ÖìÃ÷ϼ.ÌÇÄò²¡ÓëѪ˨ÐγÉ[J].ÁÙ´²ÜöÝÍ£¬2000£¬15(20)£º953

¡¡¡¡9.¡¡ÖììûÐÇ.ÏÖ´úÌÇÄò²¡[M].ÉϺ££ºÉϺ£Ò½¿Æ´óѧ³ö°æÉ磬2000.13

¡¡¡¡10.¡¡Ñ³õ£¬Ã«ÐãÆ¼.¸ßѪÌǶ¾ÐÔ×÷ÓõķÖ×Ó»úÖÆ[J].ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾£¬2001£¬17(2)£º126

¡¡¡¡11.¡¡¼ÖÇìÕÜ.ÌÇ»ù»¯ÖÕ²úÎïÔÚ¶¯ÂöÓ²»¯ÖеÄ×÷ÓÃ[J].¹úÍâҽѧÐÄѪ¹Ü¼²²¡·Ö²á£¬2001£¬28(1)£º3

¡¡¡¡12.¡¡²ÜÔÞË¹¶ÎÄÀö.ÏÖ´úΧ²úҽѧ[M].±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬2000.409~410

¡¡¡¡13.¡¡Âí»ÝÀò£¬·ë¾ü.ÏËάµ°°×Ô­Óë¹ÚÐIJ¡[J].ÐÄѪ¹Ü²¡Ñ§½øÕ¹£¬2002£¬23(6)£º326

×ªÔØÇë×¢Ã÷À´×Ô£ºhttp://www.uuqikan.com/yixuexiaoyanlw/8137.html


ÉÏһƪ£ºÒ½Ñ§½ÌÓýÖ°³Æ·¶ÎÄdz̸ҽѧÐÅÏ¢µÄ½Ìѧ¸Ä¸ï
ÏÂһƪ£ºÒ½Ñ§ÂÛÎÄ·¢±í¸ßËØÖʼìÑéҽѧ¶ÓÎéÈçºÎ¹¹½¨